Highly immunosuppressive myeloid cells correlate with early relapse after allogeneic stem cell transplantation.
Fiche publication
Date publication
mai 2024
Journal
Experimental hematology & oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE CARVALHO BITTENCOURT Marcelo, Pr RUBIO Marie Thérèse , Dr D'AVENI-PINEY Maud, Dr DE ISLA Natalia
Tous les auteurs :
Notarantonio AB, Bertrand A, Piucco R, Fievet G, Sartelet H, Boulangé L, de Isla N, De Carvalho Bittencourt M, Hergalant S, Rubio MT, D'Aveni M
Lien Pubmed
Résumé
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for myeloid malignancies such as some acute myeloid leukemias (AML) and high-risk myelodysplastic syndromes (MDS). It aims to eradicate the malignant clone using immunocompetent donor cells (graft-versus-leukemia effect, GVL). Unfortunately, relapse is the primary cause of transplant failure mainly related on HLA loss or downregulation and upregulation of inhibitory ligands on blasts which result in donor immune effector dysfunctions.
Mots clés
Allogeneic stem cell transplantation, MDSC, Relapse
Référence
Exp Hematol Oncol. 2024 05 11;13(1):50